Please wait. Loading...
 

Δημοσιεύσεις

Κατευθυντήριες Οδηγίες

  • Κατεβάστε σε μορφή pdf τις Αναθεωρημένες Κατευθυντήριες Οδηγίες της Ευρωπαικής Εταιρίας Υπέρτασης - 2009.
     
  • American Heart Association Learn and Live 2009 STEMI and PCI Focused Update
     

Newsletter

Εγγραφείτε στο Newsletter μας και μάθετε πρώτοι τα νέα και τις επερχόμενες επιστημονικές εκδηλώσεις της εταιρίας.

  •  

Με την ευγενική χορηγία:

CHIESI HELLAS


SANOFI

"Polypill" to fight cardiovascular disease

Authors' reply

EDITOR-

Your correspondents overlook the extent of the health gain achievable with the "Polypill" and of the large amount of evidence underpinning our estimates of efficacy and adverse effects.1 About one person in three would benefit, and the Polypill would offer many people important extra years of active and useful life, with benefits evident over decades. The adverse effects, on the other hand, would mostly be apparent after a few weeks, in which case a variant of the pill could be substituted-for example, one without aspirin. Of course, the Polypill is not an alternative to adopting a healthy lifestyle such as not smoking or not becoming overweight: it is a complementary means of prevention.

We agree that work on the Polypill needs to continue so that after the necessary clinical trials it can be made available. Ramos's view, that medicine should remain a patient based practice, is too limited; it would forgo important preventive measures such as vaccination. The motivation in seeking a patent for the Polypill is to help ensure its development and to fund the necessary clinical trials, which will be costly.

The expected 61% reduction in ischaemic heart disease events from statins is not twice that yet seen in any trial, as stated by Assmann et al and highlighted by White as a "spectacular claim." Randomised trials have shown this directly. In all trials that lowered low density lipoprotein cholesterol by 1.5 mmol/l (on average 1.6) (see our table 62) the average reduction in ischaemic heart disease events was 51% after two years of statin treatment. With a 1.8 mmol/l reduction the benefit will be greater, and evidence from cohort studies indicates a 61% reduction.

Although individual blood pressure lowering drugs reduce ischaemic heart disease events by about 20%, the reduction will be greater when three drugs are used together in low dosage. Trials show an additive effect on blood pressure lowering (see our figure 33), and the cohort studies show a greater reduction in disease events with greater reduction in blood pressure. Combining these two sets of data quantitatively yields the estimated 46% reduction in risk of ischaemic heart disease events. The published estimates of cost per year of life saved by using statins summarised by Messori et al are too high for four reasons. The cost of simvastatin can be expected to fall since it has recently come off patent protection.

The effect of statins in preventing heart disease has, in the past, been underestimated in trials and cohort studies as we described.4 We propose that the Polypill be used without medical examination or blood tests, so these costs are largely avoided. It is more appropriate to consider years of life gained free from a heart attack or stroke, rather than simply years of life gained. If the daily cost of the Polypill were about £1 the estimates summarised by Messori et al would be about eight times too high. On 3 September there were 88 rapid responses to our papers on bmj.com.

We classified 24 as positive, 41 as negative, and 23 as raising related side issues. The responses ranged from rating the work as Nobelian to regarding it as a joke. We were struck by the strength of negative feeling by doctors on the use of a daily pill to prevent major disease. The public seems to think otherwise. The CNN website asked, "Would you take the Polypill?" and 95% replied yes. As DePoy says in his tongue in cheek summary of the responses, some regard the Polypill as immoral, and some thought, illogically, that it might benefit the population as a whole but individual patients would be worse off on average.5 White's summary concentrates on the hyperbole.

She does not comment on the lack of scientific input to the debate but selects invalid assertions such as "lack of trial evidence," the work being based on "flawed Framingham study data," and she makes the incorrect assumption of "perfect synergy." Your correspondents have not given reason or evidence against the concept of the Polypill. Many have not recognised the massive data available on the efficacy and adverse effects of the Polypill components or the evidence showing their independent effects which together form the basis of our estimates. The fact that the expected health benefit is large is a reason for supporting it, not a reason for disbelieving it. Nicholas Wald, professor  

Κατεβάστε την ολοκληρωμένη δημοσίευση σε μορφή pdf.

 

 

© 2010-2014 Hellenic Society of Cardiovascular Prevention. All rights reserved.